Non-invasive biomarkers for chronic hepatitis B virus infection management
Caroline Charrea,b,c, Massimo Levreroa,b,d, Fabien Zoulima,b,d, Caroline Scholtèsa,b,c,*
a INSERM U1052-Cancer Research Center of Lyon (CRCL), 69008, Lyon, France
b University of Lyon, University Claude Bernard Lyon 1 (UCBL1), Lyon, France
c Department of Virology, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
d Department of Hepatology, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France
A B S T R A C T
Chronic hepatitis B virus (HBV) infection remains a major health burden with over 250 million cases worldwide.
This complex infection can lead to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Complete recovery is seldom achieved due to the persistence in infected hepatocytes of covalently closed circular (ccc) DNA, which is not targeted by current antiviral therapies. Routine circulating biomarkers used for clinical monitoring of patients do not accurately reflect the cccDNA pool and transcriptional activity. New biomarkers,
such as serum HB core-related Ag and circulating HBV RNAs, are under development. In this review, we discuss surrogate non-invasive biomarkers for evaluating intrahepatic cccDNA abundance and transcriptional activity.
We also present their relevance for improving the classification of patients with regards to their natural history and for evaluating novel compounds to assess target engagement and to define new virological endpoints.作者: StephenW 时间: 2019-9-8 20:27
用于慢性乙型肝炎病毒感染管理的非侵入性生物标志物
Caroline Charrea，b，c，Massimo Levreroa，b，d，Fabien Zoulima，b，d，CarolineScholtèsa，b，c，*
INSERM U1052-里昂癌症研究中心（CRCL），69008，法国里昂
b里昂大学Claude Bernard Lyon 1（UCBL1），法国里昂
c法国里昂Cropils de Lyon收容所Croix Rousse医院病毒学系
d法国里昂里昂市中心收容所Croix Rousse医院肝病科
A B S T R A C T.
慢性乙型肝炎病毒（HBV）感染仍然是一个主要的健康负担，全世界有超过2.5亿病例。
这种复杂的感染可导致慢性肝炎，肝硬化和肝细胞癌。由于共价闭合环状（ccc）DNA的感染肝细胞持续存在而很难实现完全恢复，这不是目前抗病毒疗法的目标。用于临床监测患者的常规循环生物标志物不能准确反映cccDNA库和转录活性。新的生物标志物，
如血清HB核相关Ag和循环HBV RNA正在开发中。在这篇综述中，我们讨论了替代非侵入性生物标志物，用于评估肝内cccDNA丰度和转录活性。
我们还提出了改善患者自然病史分类的相关性，以及评估新化合物以评估目标参与度和定义新的病毒学终点的相关性。作者: StephenW 时间: 2019-9-8 20:27